As a follow-up to my post from last week, the biotech fund is indeed pushing toward H&S completion. Rather remarkable, considering everything else going on in the market. It’s also kind of ironic, considering how the latest excitement is about the “breakthrough” Covid therapy. In any case, this is almost reaching the failure zone.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.